October 7, 2020 10:38 AM EDTUpdated 10:48 AM
R&D
Coronavirus

Af­ter two rounds of mixed da­ta, Eli Lil­ly im­press­es an­a­lysts with new Covid-19 an­ti­body re­sults. And ex­ecs want an EUA now

Jason Mast

Editor

Eli Lil­ly has more da­ta from their Covid-19 neu­tral­iz­ing an­ti­bod­ies — da­ta, they say, should war­rant an FDA OK.

The Big Phar­ma said Wednes­day that a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times